Scarica l'app Stockscreener
2.55
2.00%
0.05
Dopo l'orario di chiusura:
2.55
Cellectar Biosciences Inc Borsa (CLRB) Ultime notizie
Earnings call transcript: Cellectar Biosciences Q4 2025 reveals strategic cost control - Investing.com
Aug Technicals: Will Cellectar Biosciences Inc outperform during market ralliesOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Smart Money: Is Cellectar Biosciences Inc a top pick in the sectorQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
VIX Spike: Can Cellectar Biosciences Inc weather a recessionTrade Risk Assessment & Community Verified Trade Alerts - baoquankhu1.vn
What drives Cellectar Biosciences Incs stock price2026 Risk Factors & Weekly High Potential Stock Alerts - baoquankhu1.vn
ETF Watch: Will WASH benefit from geopolitical trendsShare Buyback & Stepwise Trade Signal Implementation - baoquankhu1.vn
Big Money Moves: How cyclical is Cellectar Biosciences Incs revenue streamTrade Entry Report & Smart Swing Trading Alerts - baoquankhu1.vn
If You Invested $1,000 in Cellectar Biosciences Inc (CLRB) - Stock Titan
Meme Stocks: Can Cellectar Biosciences Inc disrupt its industryMarket Trend Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Aug Patterns: How does Cellectar Biosciences Inc compare to its peers2026 Volume Leaders & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Layoff Watch: Will Cellectar Biosciences Inc stock benefit from M A2026 Earnings Impact & Fast Moving Market Watchlists - baoquankhu1.vn
Trading Recap: Can Cellectar Biosciences Inc weather a recessionWeekly Investment Report & Safe Capital Investment Plans - baoquankhu1.vn
Risk Report: Does Cellectar Biosciences Inc have a sustainable dividendTake Profit & Daily Stock Trend Watchlist - baoquankhu1.vn
Rate Cut: Can Cellectar Biosciences Inc weather a recessionMarket Growth Report & Short-Term Trading Alerts - baoquankhu1.vn
Cellectar Biosciences (NASDAQ:CLRB) Rating Increased to Buy at Maxim Group - Defense World
CLRB: Maxim Group Upgrades Cellectar Biosciences to Buy with $10 Target | CLRB Stock News - GuruFocus
Ideas Watch: Can Cellectar Biosciences Inc weather a recessionPortfolio Profit Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally - MSN
Cellectar Biosciences Charts Risky Path to Approvals - TipRanks
Quarterly Trades: Does Cellectar Biosciences Inc have a sustainable dividendJuly 2025 Macro Moves & Long-Term Growth Plans - baoquankhu1.vn
Can Cellectar Biosciences Inc weather a recessionWeekly Trading Summary & Safe Capital Growth Plans - baoquankhu1.vn
Should you sell your Cellectar Biosciences stock? - Cantech Letter
Death Cross: Is Cellectar Biosciences Inc vulnerable to short sellersMarket Rally & Capital Efficiency Focused Ideas - baoquankhu1.vn
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale - AOL.com
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2025 Earnings Call Transcript - Insider Monkey
Cellectar (CLRB) Marks Significant Achievements in 2025 - GuruFocus
Cellectar Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cellectar (CLRB) Q4 2025 Earnings Call Transcript - The Globe and Mail
CLRB: Advanced late-stage pipeline, improved financials, and set up for major regulatory milestones in 2026 - TradingView
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates - Investing News Network
CLRB: Advanced regulatory progress, reduced losses, and extended cash runway position for key 2026 milestones - TradingView
Cellectar Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Summary: Cellectar Biosciences (CLRB) FY25 net loss narrows - AlphaStreet News
CLRB: Net loss narrowed to $21.8M in 2025, but new funding is needed beyond Q3 2026 - TradingView
CLRB: Net loss narrowed as pipeline advanced toward key regulatory and clinical milestones - TradingView
Cellectar Biosciences 2025 10-K — Net loss $8.35 EPS; no revenue reported - TradingView
Cellectar (NASDAQ: CLRB) halves 2025 loss while pushing key cancer drugs - Stock Titan
Iopofosine progress at Cellectar (NASDAQ: CLRB) with pivotal WM data and FDA path - Stock Titan
Cellectar Biosciences, Inc. Advances Iopofosine I-131 Submission for Waldenström Macroglobulinemia and Initiates Phase 1b Study of CLR 125 in Triple Negative Breast Cancer - Quiver Quantitative
Insights into Cellectar Biosciences's Upcoming Earnings - Benzinga
Cellectar Biosciences, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Cellectar Biosciences Inc expected to post a loss of $2.02 a shareEarnings Preview - TradingView
Cellectar Biosciences (CLRB) to Release Earnings on Wednesday - Defense World
Rate Cut: Is Cellectar Biosciences Inc currently under institutional pressureJuly 2025 PreEarnings & AI Forecast Swing Trade Picks - baoquankhu1.vn
CLRB SEC FilingsCellectar Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Analyst Upgrade: Will Cellectar Biosciences Inc benefit from rising consumer demandMarket Sentiment Summary & Capital Protection Trade Alerts - baoquankhu1.vn
CLRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Nasdaq Moves: How cyclical is Cellectar Biosciences Incs revenue streamMarket Performance Recap & High Accuracy Trade Alerts - baoquankhu1.vn
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 - Investing News Network
CLRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cancer-drug developer Cellectar sets March 4 call on 2025 results - Stock Titan
Bull Bear: What drives Cellectar Biosciences Inc.’s stock priceQuarterly Profit Review & AI Forecasted Entry and Exit Points - mfd.ru
Gap Down: What are Cellectar Biosciences Incs growth leversJuly 2025 Action & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition - AOL.com
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - AOL.com
Cellectar Biosciences Expands Global Intellectual Property Estate - Investing News Network
Cellectar Biosciences Expands Global Intellectual Property Portfolio Ahead of Iopofosine I 131 Marketing Approval for Waldenström Macroglobulinemia - Quiver Quantitative
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):